Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study

Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and survival were performed in patients from REACH.Serum AFP was measured at baseline and every 3 cycles (2 weeks/cycle). Associations between AFP and radiographic progression and efficacy end points were analysed.Median percent AFP increase from baseline was smaller in the ramucirumab than in the placebo arm throughout treatment. Time to...